A Drug for CKD?

 Now that I’ve used all the information in my book (still at the printers, folks), I’ve been cruising all over the web to see what’s happening with our disease. I found the following article about a drug – yes, that’s right, a drug – that just might be really helpful.  I suddenly became very hopeful, despite my warning you not to get your hopes up about things that MIGHT be useful in slowing down  CKD.

What caught me off guard about the current CKD treatment is the following statement from the article, “Despite the use of current treatments, many patients progress to renal failure.” I don’t want to be one of those patients.  I want this novel approach drug to be developed before I need dialysis.  I want  kidneys to be grown in labs before I need a new one. I want stem cell research to provide more ways to improve the lives of those on dialysis.  But, this article seems to offer the simplest solution: a drug to impede the slowing down of kidney function.

Until any one of the new advancements is ready for us, I’ll continue to stick to the renal diet, take the meds that have been prescribed and exercise for half an hour a day… while I hope.

Concert Pharmaceuticals Advances Novel Chronic Kidney Disease Treatment, CTP-499, in Phase 1 Clinical Study

 
First-in-Class Drug Candidate from Deuterium Platform Has Anti-Inflammatory, Anti-Fibrotic, and Anti-Oxidant Properties

LEXINGTON, Mass.–(BUSINESS WIRE)–Mar 29, 2011 – Concert Pharmaceuticals, Inc. today announced it has made significant progress advancing CTP-499, its novel anti-inflammatory, anti-oxidant, and anti-fibrotic agent for diabetic nephropathy and other forms of chronic kidney disease, into clinical development. Based on encouraging preclinical results and successful formulation assessment in healthy volunteers, Concert has initiated a Phase 1 single ascending dose study of CTP-499 in healthy volunteers. CTP-499, invented using Concert’s DCE Platform™ (deuterated chemical entity platform), is a potential first-in-class treatment for chronic kidney disease, a major and growing health problem.

“We are excited about the progress of CTP-499 and its potential to treat diabetic nephropathy and, more generally, chronic kidney disease,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “Chronic kidney disease is a progressive disease that has become a major medical concern associated with substantial health care costs running to tens of billions of dollars per year in the US. Preclinical evidence that CTP-499 may protect kidney function and slow disease progression is encouraging. We look forward to advancing CTP-499 in clinical testing to evaluate its benefits in the treatment of diabetic nephropathy and other forms of chronic kidney disease.”

Diabetic nephropathy is associated with diabetes and is the leading cause of chronic kidney disease in the US. Current standard of care for kidney disease is treatment with blood pressure lowering agents that affect the renin-angiotensin cascade, including Angiotensin Converting Enzyme inhibitors (ACEi) and Angiotensin Receptor Blockers (ARBs). Despite the use of current treatments, many patients progress to renal failure. There is a critical need for agents with novel mechanisms that further delay or prevent the decline of kidney function.

There is more technical information about this drug in the rest of the article.  I could barely keep up with what I’d read so I didn’t include it here, but you can read it at: http://www.drugs.com/clinical_trials/concert-pharmaceuticals-advances-novel-chronic-kidney-ctp-499-phase-1-clinical-study-11383.html

I’ll keep chewing on this one and seeing if I can wrap my mind around it: a drug to slow down CKD!

Until Friday,

Keep living

Advertisements
Published in: on May 10, 2011 at 11:28 pm  Comments (9)  

The URI to TrackBack this entry is: https://gailraegarwood.wordpress.com/2011/05/10/a-drug-for-ckd/trackback/

RSS feed for comments on this post.

9 CommentsLeave a comment

  1. CTP-499 is the deuterated version of hydroxypentoxifylline, a reversible metabolite [“S-M1”] & therefore sometime precursor of pentoxifylline. There is a HUGE medical literature on the use of pentoxifylline [PTX] in kidney disease — and PTX, or “pentox” is very cheap — between $1.25 and $3.00 for a day’s dose. http://www.ncbi.nlm.nih.gov/pubmed?term=pentoxifylline%20kidney In other words, while CTP-499 will be once-a-day dosing rather than 3 to 6 times-a-day dosing, and it is said to have less incidence of nausea — which is rather rare, anyway — you might as well start using PTX now, rather than wait for CTP-499.

    • Thank you, Dr. Powell. I did look at the abstracts you sent, but am not well enough versed in medical terminology to fully understand them. I would suggest that any readers interested in CTP-499 or pentoxifylline, either read the abstracts themselves or bring them to their nephrologists. I am neither endorsing or negating the suggestions.

  2. A review just appeared noting the usefulness of pentoxifylline [PTX], plus several other older medications, in diabetic kidney disease. You will be hearing a lot more about PTX & its derivatives [currently 3 new such medications are in the pipeline]. Again, I would start using PTX now as it has a long track record, a good safety profile & is quite cheap. http://www.ncbi.nlm.nih.gov/pubmed/22578309
    Clin Ther. 2012 May 10. [Epub ahead of print]
    “Update on Potential Drugs for the Treatment of Diabetic Kidney Disease.” Shepler B, Nash C, Smith C, Dimarco A, Petty J, Szewciw S. Source: Purdue University College of Pharmacy, West Lafayette, Indiana. Abstract: BACKGROUND: Although controlling hyperglycemia and proteinuria is currently the main focus of diabetic kidney disease management, some existing drugs and other new compounds are being evaluated for their ability to interrupt the disease process. Specifically, drugs that interfere with the formation and action of advanced glycation end products and reduce or inhibit fibrosis of the glomerular structures in the presence of hyperglycemia are just 2 examples. … CONCLUSIONS: Pirfenidone, doxycycline, bardoxolone, pentoxifylline, ruboxistaurin, pyridoxamine, paricalcitol, FG-3019, AST-120, and allopurinol have shown beneficial effects in treating patients with DKD through modification of the pathologic mechanisms by which hyperglycemia alters the structure and function of the glomerulus. … Copyright © 2012 Elsevier HS Journals, Inc. All rights reserved.PMID: 22578309

    • Thank you, Dr. Powell. I did look at the abstracts you sent, but am not well enough versed in medical terminology to fully understand them. I would suggest that any readers interested in CTP-499 or pentoxifylline, either read the abstracts themselves or bring them to their nephrologists. I am neither endorsing or negating the suggestions. I also know very little, if anything, about diabetic specific chronic kidney disease. Please careful, readers, but take a look at the article.

  3. Have you heard of Bardoxolone, It is in Phase 3 It is abbots shinning star for the future, so far not only does it slow down the progression chronic kidney disease but improves it, Phase one & two were very positive. If all goes well they think it may be out in 2014, that is the drug I am waiting for
    Colleen

    • Colleen,

      The trial has been ended due to multiple deaths. I caution you to reconsider your thought about Bardozolone.

      • Yes, I have heard that the drug Bardoxolone was discontinued do to deaths. I am very sad to hear that the drug had so much promese and went through phase I & Phase II very well. I only can hope that they don’t drop it completely, It was a cancer drug and they noticed that the side effects helped chronic kidney disease .
        Colleen

  4. I have been researching this drug. Seemingly, it is for late stage ckd caused by diabetes. While it does seem successful, there is still a question about the raised albumin levels. The side effects can be difficult, too, so I would take a wait-see attitude for the results of the phase 3 trials. As someone who is not looking forward to dialysis in my own future, I am very excited at what this drug COULD mean for those with ckd and diabetes even though I am not in that group.

    • Even though you are not in that group, that does not mean you could not be helped by this drug, If and when it gets approved, it is going to treat in a different way, treating the inflamation. In everything that I have read the side effects are minor ( muscle spasms) and yes they are treating late stage ckd, but what better people to help?
      Colleen


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s